BND vs IBB

Vanguard Total Bond Market ETF vs iShares Biotechnology ETF

Quick take
  • • BND has the lower expense ratio at 0.03% vs 0.44% for IBB.
  • • BND pays a higher dividend yield (4.11%).

Side-by-side metrics

MetricBNDIBB
Expense ratio
Annual fee. Lower is better.
0.03%0.44%
Dividend yield
Trailing 12-month yield.
4.11%0.16%
AUM
Assets under management — bigger funds are typically more liquid.
$400.61B$11.50B
YTD return
0.03%30.22%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.980.60
P/E ratio
—25.48
Last price
$71.09$217.75
Inception
——
Issuer
VanguardiShares

BND top holdings

Holdings data unavailable for BND.

IBB top holdings

Top holdings · IBB
GILDGilead Sciences Inc8.94%
AMGNAmgen Inc8.31%
VRTXVertex Pharmaceuticals Inc7.87%
REGNRegeneron Pharmaceuticals Inc6.24%
MRNAModerna Inc5.49%
NTRANatera Inc3.78%
ARGXargenx SE ADR3.36%
BIIBBiogen Inc2.52%
RVMDRevolution Medicines Inc Ordinary Shares2.50%
ILMNIllumina Inc2.41%
Sector breakdown · IBB
Healthcare100.0%

About BND

BND (Vanguard Total Bond Market ETF) is Broad exposure to US investment-grade bonds. Managed by Vanguard, the fund carries $400.6B in assets under management, an expense ratio of 0.03%, a dividend yield of 4.11%.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.